Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer.
通过抑制 BCL-2 增强阿霉素在 p53 野生型和突变型三阴性乳腺癌中的活性
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1549282
Schreiber Anna R, Smoots Stephen G, Jackson Marilyn M, Bagby Stacey M, Dus Evan D, Dominguez Adrian T A, Binns Cameron A, Pitts Todd M, Diamond Jennifer R
